We Need More Proof That Prenatal Gene Screens Are Beneficial
By The Editors,
Scientific American
| 02. 01. 2016
Untitled Document
Expecting a baby often provokes mixed emotions—wonder and amazement but also concern. Will the child be healthy? Happy? Find his or her spot in the world? Several prenatal blood tests are now available that attempt to ease some of the anxiety—at least about health. By analyzing trace amounts of fetal DNA in a pregnant woman's bloodstream, these tests (which go by such names as Harmony, MaterniT21 PLUS and verifi) can identify various genetic anomalies up to six months before birth. Whether or not parents to be take advantage of these laboratory measures is, of course, up to them. But results from screening tests can be misleading, and industry and federal regulators are not doing enough to ensure that people get all the information they need.
At present, the tests detect major abnormalities—such as three copies of the 21st, 18th or 13th chromosome, which lead, respectively, to Down, Edwards and Patau syndrome. These measures are a definite safety improvement over earlier procedures to check the genes of the unborn. Previously such chromosomal abnormalities could be detected prenatally only by...
Related Articles
By Keith Casebonne and Jodi Beckstine [with CGS' Katie Hasson], Disability Deep Dive | 07.24.2025
In this episode of Disability Deep Dive, hosts Keith and Jodi explore the complex interplay between disability science, technology, and ethics with guest Katie Hasson, Associate Director at the Center for Genetics and Society. The conversation delves into...
By Angus Liu, Fierce Pharma | 07.22.2025
A brief skirmish between Sarepta Therapeutics and the FDA has ended before escalating into a full-on regulatory clash, as the company has bowed to the agency’s demand.
In a surprising reversal, Sarepta on Monday said it will pause all shipments...
By Lucy Tu, The Atlantic | 07.11.2025
Donald Trump—who is, by his own accounting, “the fertilization president” and “the father of IVF”—wants to help Americans reproduce. During his 2024 campaign, he promised that the government or insurance companies would cover the cost of in vitro fertilization. In...
By Jared Whitlock, Endpoints News | 07.15.2025
Patient groups face a harder and unpredictable path going state-by-state to boost screening for rare but treatable conditions after the Trump administration disbanded a federal advisory committee on newborn screening.
In April, the Advisory Committee on Heritable Disorders in Newborns...